Science | Nutrition
Bitter Melon
Bitter melon (Momordica charantia) is a tropical fruit known for its potential benefits in managing diabetes. Studies suggest it may help lower blood sugar levels by enhancing insulin secretion. Additionally, bitter melon has been explored for its anti-inflammatory, anti-cancer, and cardiovascular protective properties. While its hypoglycemic effects are modest, it may serve as a supplementary treatment for type 2 diabetes.
PUBLICATIONS
The Effects of Bitter Melon (Mormordica charantia) on Lipid Profile: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Phytother Res. 2024 Oct 23. doi: 10.1002/ptr.8357
Design: Systematic review and meta-analysis
Summary: This study investigated the impact of bitter melon consumption on lipid profile, showing a significant reduction in total cholesterol (TC) and triglyceride (TG) levels but no significant effects on LDL-C and HDL-C levels. The study concluded that bitter melon may help manage dyslipidemia but noted the limitations of short-term trials.
Effects of Momordica charantia L. supplementation on glycemic control and lipid profile in type 2 diabetes mellitus patients: A systematic review and meta-analysis of randomized controlled trials
Heliyon. 2024 May 11;10(10):e31126. doi: 10.1016/j.heliyon.2024.e31126
Design: Systematic review and meta-analysis
Summary: The study explored the effect of Momordica charantia supplementation in patients with type 2 diabetes, showing a significant reduction in fasting blood glucose, postprandial glucose, and glycosylated hemoglobin A1c. However, no significant impact was found on triglycerides, HDL, or LDL levels.
Hypoglycemic efficacy and safety of Momordica charantia (bitter melon) in patients with type 2 diabetes mellitus
Complement Ther Med. 2020 Aug;52:102524. doi: 10.1016/j.ctim.2020.102524
Design: Randomized, placebo-controlled study
Summary: The study evaluated the glucose-lowering efficacy of bitter melon in type 2 diabetes patients, showing a significant decrease in fasting glucose levels, but no change in glycated hemoglobin (HbA1c) levels after 12 weeks of treatment. No serious adverse events were reported during the treatment period.
Momordica charantia L. lowers elevated glycaemia in type 2 diabetes mellitus patients: Systematic review and meta-analysis
J Ethnopharmacol. 2019 Mar 1;231:311-324. doi: 10.1016/j.jep.2018.10.033
Design: Systematic review and meta-analysis
Summary: This meta-analysis assessed the effects of Momordica charantia on glycemic control in type 2 diabetes patients, showing significant reductions in fasting plasma glucose, postprandial glucose, and HbA1c levels. No significant adverse effects were reported, but the evidence quality was downgraded due to study limitations.
Momordica charantia Administration Improves Insulin Secretion in Type 2 Diabetes Mellitus
J Med Food. 2018 Jul;21(7):672-677. doi: 10.1089/jmf.2017.0114. Epub 2018 Feb 12.
Design: Randomized, double-blinded, placebo-controlled, clinical trial
Summary: A study examining the effect of Momordica charantia (bitter melon) administration on insulin secretion and sensitivity in patients with type 2 diabetes. The results showed significant reductions in weight, BMI, and HbA1c, along with an increase in insulin secretion, but no changes in insulin sensitivity.
Lower hypoglycemic but higher antiatherogenic effects of bitter melon than glibenclamide in type 2 diabetic patients
Nutr J. 2015 Jan 26;14:13. doi: 10.1186/1475-2891-14-13.
Design: Randomized trial comparing the effects of bitter melon and glibenclamide
Summary: This study found that while bitter melon had a weaker hypoglycemic effect compared to glibenclamide, it was more effective at improving cardiovascular risk factors associated with diabetes.
Hypoglycemic effect of bitter melon compared with metformin in newly diagnosed type 2 diabetes patients
J Ethnopharmacol. 2011 Mar 24;134(2):422-8. doi: 10.1016/j.jep.2010.12.045.
Design: Multicenter, randomized, double-blind, active-control trial
Summary: This trial assessed the efficacy and safety of bitter melon compared with metformin. The 2,000 mg/day bitter melon dose showed modest hypoglycemic effects, but less effective than metformin 1,000 mg/day.
